A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
about
Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis.Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.Focus on Nintedanib in NSCLC and Other TumorsPhase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment.Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.The potential role of nintedanib in treating colorectal cancer.Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer."Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer.Nintedanib in ovarian cancer.Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
P2860
Q30249619-1DA3D4A8-93C4-41A3-9B27-F16A4FD3B13DQ36137504-F2094B04-4400-4B67-A9D4-230410C4EF5BQ37512962-DFFE014C-FA2F-4462-AF91-1FA540347DD7Q37544401-1729C076-AC80-4309-9E15-E5738DA39D9DQ37632167-FA6B3D65-0571-4AE5-9BAD-E91847722BADQ38679229-D7333CD0-EB25-4B86-BE69-34F850E113BDQ38759141-4E4F61B9-5A5B-4AA5-BE05-13B0BE60B860Q38941928-A3F03AF8-FC00-45CC-BCD2-9F1FE0720069Q39398037-24DD611F-5F91-478B-986D-2C75AB672DDCQ42367389-81019F8B-8894-417C-A33A-CF9C83320752Q47719824-134AEA4F-62E2-4A91-B915-0C96A90E5B9BQ48207420-806883DE-E3A2-450E-BAEF-681784A3CD83Q51824301-58E21550-2419-4996-81F4-08BFA37E9A52Q52816718-62328032-53FD-489E-9DE1-17514B0AF926
P2860
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase I/II, open-label, rand ...... ic colorectal cancer patients.
@en
type
label
A phase I/II, open-label, rand ...... ic colorectal cancer patients.
@en
prefLabel
A phase I/II, open-label, rand ...... ic colorectal cancer patients.
@en
P2093
P2860
P356
P1433
P1476
A phase I/II, open-label, rand ...... tic colorectal cancer patients
@en
P2093
E Van Cutsem
H Dressler
J Bennouna
J Capdevila
P2860
P304
P356
10.1093/ANNONC/MDV286
P50
P577
2015-08-12T00:00:00Z